A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

This study tests whether a combination of a Trop-2-targeting antibody-drug conjugate (a type of precision cancer drug) with other treatments works better for people with advanced triple-negative breast cancer (TNBC) — one of the most aggressive forms of breast cancer. TNBC is called "triple-negative" because the tumor lacks three common receptors that many effective breast cancer drugs target. **You may be eligible if:** - You are between 18 and 70 years old - You have biopsy-confirmed triple-negative invasive breast cancer - You have advanced (metastatic) disease - You are in reasonably good physical health **You may NOT be eligible if:** - You are over 70 years old - Your cancer is not confirmed to be triple-negative - You have serious organ damage (heart, liver, kidney) - You are pregnant or breastfeeding - You have certain other active cancers Talk to your doctor to see if this trial is right for you.